Hexarelin vs sermorelin vs tesamorelin: how they differ

Last updated 2026-07-24

What is the basic difference between hexarelin, sermorelin, and tesamorelin?

All three peptides push the pituitary to release more growth hormone, but they use two different biological doors to do it. Sermorelin and tesamorelin are both growth hormone-releasing hormone (GHRH) analogs. They mimic the natural hypothalamic hormone that tells the pituitary "release GH now," and they only work if the pituitary still has healthy GH-producing cells to respond ^[1]. Hexarelin is a different animal. It's a synthetic growth hormone secretagogue, part of the same family as ghrelin mimetics like ipamorelin and GHRP-6. It binds the ghrelin receptor (GHSR-1a) rather than the GHRH receptor, and it triggers GH release through a separate pathway that also touches appetite, cortisol, and prolactin signaling ^[2]. The practical upshot: sermorelin and tesamorelin tend to produce a more physiologic, pulsatile GH release that mirrors the body's own rhythm. Hexarelin produces a bigger, blunter GH spike, and it desensitizes fast, meaning repeated dosing loses potency within days to weeks in published pharmacology work ^[2]. None of these three is human growth hormone itself. If you want the fuller answer on how a GHRH analog stacks up against injecting HGH directly, that's covered on the sermorelin overview page.

Is sermorelin FDA approved, and what happened to Geref?

Sermorelin acetate was FDA approved and sold in the US under the brand name Geref starting in the 1990s, for diagnostic testing of pituitary GH reserve and for treating certain cases of growth hormone deficiency in children ^[3]. Geref is no longer marketed in the United States. The manufacturer discontinued the branded product for commercial reasons, not because of a safety recall or an FDA-mandated withdrawal. That distinction matters because people often assume 'no longer on the market' means 'pulled for danger.' It didn't happen that way here. FDA's own discontinued drug listings reflect a business discontinuation, and sermorelin remains legally available today mainly through compounding pharmacies operating under a prescription, since no company currently holds an active, marketed FDA-approved sermorelin product in the US ^[4]. That compounded status is worth sitting with for a second. It means sermorelin doesn't go through the same batch-by-batch FDA approval scrutiny a still-marketed drug does; quality depends heavily on which pharmacy fills it. This is a good moment to check a pharmacy's accreditation before you commit, something the sermorelin reviews page walks through in more detail.

Is tesamorelin FDA approved, and what is it approved for?

Yes, and this is the one clear FDA approval in this trio. Tesamorelin (brand name Egrifta, and the follow-on Egrifta SV) is FDA-approved specifically to reduce excess abdominal fat in HIV-infected patients with lipodystrophy ^[5]. It is not approved as a general anti-aging therapy, a bodybuilding aid, or a treatment for age-related GH decline in people without HIV-associated lipodystrophy. The trials behind that approval, published in the New England Journal of Medicine, showed measurable reduction in visceral adipose tissue over 26 weeks compared to placebo, which is why the indication is narrow and specific rather than broad ^[6]. Prescribers do sometimes use tesamorelin off-label for other GH-related goals, but insurers and the label reflect that one approved use. Hexarelin, in contrast, has never gone through FDA review for any human indication in the US. It's sold as a research chemical, not a prescription drug, and any human use happens outside FDA-regulated dosing standards.

How do hexarelin, sermorelin, and tesamorelin compare side by side?

Here's the head-to-head most people actually want, condensed into one table.

How does dosing differ between the three peptides?

Sermorelin is typically dosed once daily by subcutaneous injection, usually at bedtime, to work with the body's natural nighttime GH pulse. Clinical and compounding pharmacy protocols commonly land in a range of roughly 0.1 to 0.3 mg per day for adults, though exact numbers vary by prescriber and by why someone is using it. The original Geref label for adults used weight-based dosing for its diagnostic indication, not a flat daily number, which is one reason today's off-label adult dosing looks different from the historic package insert ^[3]. Anyone starting sermorelin should ask their prescriber which reference range they're using and why; the sermorelin dosage chart and sermorelin dosage calculator break down common starting points and how they scale. Tesamorelin's FDA-approved dosing for Egrifta SV is 1 mg injected subcutaneously once daily, reconstituted by the patient or caregiver following the label's mixing instructions ^[5]. That number is not a suggestion pulled from a forum; it's the labeled dose studied in the approval trials. Hexarelin has no standardized human clinical dose because it was never brought through an approval process for any indication. Older pharmacology papers tested it at microgram-per-kilogram doses in short research studies, sometimes multiple times a day, but there is no regulatory body, package insert, or consensus clinical protocol to point to. Anyone using it is essentially self-experimenting with a research chemical outside dosing standards that exist for the other two.

Which one is better for fat loss?

If fat loss is specifically visceral abdominal fat in the context of HIV-associated lipodystrophy, tesamorelin is the only one of the three with FDA approval and randomized trial evidence behind that exact use ^[5][6]. That's a narrow lane, but it's a real one, backed by phase 3 data. For general fat loss in people without that condition, none of the three has strong, dedicated randomized controlled trial evidence showing meaningful fat loss as a primary approved outcome. Sermorelin's studied benefits center on restoring more normal GH pulsing in people with diagnosed deficiency, not on cosmetic fat reduction in otherwise healthy adults. Hexarelin's fat-related data is thin, older, and mostly mechanistic or animal-based. Be skeptical of any provider or product page promising dramatic body recomposition from sermorelin or hexarelin. That's marketing outrunning the evidence, not something a peer-reviewed trial has actually shown for those two compounds.

What are the side effects of each, and which has the worst safety profile?

Sermorelin's reported side effects in clinical literature and compounding pharmacy labeling tend to be mild: injection site redness or itching, flushing, headache, and occasionally dizziness. Long-term human safety data is limited precisely because large modern trials haven't been run on it recently; most of what regulators reviewed came from the Geref era. The sermorelin long-term side effects page goes through what is and isn't known here in more depth. Tesamorelin's label lists injection site reactions, joint pain (arthralgia), swelling in the arms or legs, and increases in blood glucose or IGF-1 as documented effects in trial data, since it's an approved drug with a formal adverse event profile spelled out for prescribers and patients ^[5]. People with active malignancy or pituitary tumors are specifically cautioned against use per that labeling. Hexarelin's side effect concerns are structurally different and, in the view of most endocrine reviews on GH secretagogues, more concerning for casual use. Because it acts through the ghrelin receptor, it tends to raise cortisol and prolactin alongside GH, effects not typically seen with GHRH analogs at studied doses ^[2]. Elevated prolactin can cause symptoms like breast tenderness or menstrual changes, and chronically elevated cortisol carries its own downstream risks. Combined with fast tachyphylaxis (the drug losing effect with repeated dosing), hexarelin has the least favorable risk-to-reward profile of the three when judged by what's actually been published.

Sermorelin vs HGH: which is the better choice?

This is probably the real question underneath all of it, so it deserves a straight answer. Sermorelin stimulates your own pituitary to make and release GH; injectable HGH (somatropin) is the hormone itself, made recombinantly and given directly. They are not interchangeable, and each has a real advantage the other doesn't. Sermorelin's advantage is that it works with your body's own feedback loops. Because the pituitary still controls final output, and natural negative feedback (via somatostatin) still applies, sermorelin is much less likely to push GH or IGF-1 to the kind of supraphysiologic levels associated with HGH's known risks: joint pain, carpal tunnel-like symptoms, fluid retention, and in some contexts elevated cancer or cardiovascular concern seen in studies of GH excess. Sermorelin also fails outright in people whose pituitary can't respond, which is itself diagnostically useful and a real limitation, not a footnote. HGH's advantage is directness and predictability. If someone has severe adult GH deficiency confirmed by stimulation testing, or a pituitary that genuinely can't produce enough GH regardless of GHRH stimulation, sermorelin simply won't work as well, because it needs a functioning gland to act on. In that scenario, recombinant HGH is the evidence-based, FDA-approved path, and sermorelin is the weaker choice by mechanism, not by marketing spin. For someone with a working pituitary who wants a gentler nudge toward more normal GH pulsing, sermorelin is the more physiologic option and generally the one with a milder side effect profile at labeled or typical off-label doses. For someone with confirmed severe deficiency or pituitary failure, HGH is the more reliable and better-studied choice. Neither is a validated anti-aging treatment for healthy adults with normal GH levels, and no reputable clinical guideline recommends using either one that way.

How do the three compare on cost and access?

Tesamorelin, as a branded FDA-approved drug (Egrifta SV), typically carries the highest list price of the three, often running into four figures per month before insurance, since it's a specialty biologic-adjacent product with a narrow approved population and limited generic competition. Insurance coverage generally requires the specific HIV lipodystrophy diagnosis on the label. Sermorelin, because it's compounded rather than commercially branded in the US now, tends to be priced by the compounding pharmacy per vial or per month of supply, and costs vary a lot by pharmacy, dose, and region. It's compounded, not FDA-batch-approved, so price differences often track quality and sourcing rather than pure markup. Finding a legitimate, provider-reviewed source matters more here than for a standard retail pharmacy drug; the sermorelin peptide near me page covers how to vet a source. Hexarelin is typically sold as a 'research chemical,' often cheaper per vial than either legitimate pharmaceutical option, but that low price reflects the complete absence of FDA oversight, GMP manufacturing verification, or quality control most people would want in something they inject.

Can hexarelin, sermorelin, and tesamorelin be combined or stacked?

Combining a GHRH analog (sermorelin or tesamorelin) with a ghrelin-mimetic secretagogue (like hexarelin, or its more commonly stacked cousin ipamorelin) is a common pattern in the peptide community, based on the idea that the two mechanisms are additive since they hit different receptors. Some small pharmacology studies do show additive GH release when GHRH and GHS-pathway compounds are given together ^[2]. That additive mechanism is real in short-term lab measurements of GH output. It is not the same thing as a demonstrated long-term safety or efficacy benefit for a health goal in humans. Nobody has run a large randomized trial testing a sermorelin-plus-hexarelin stack for any approved indication, so a prescriber recommending this combination is working from mechanism and small studies, not from outcomes data. Combining tesamorelin with hexarelin raises the same open questions, plus the fact that tesamorelin already has an approved, tested standalone protocol for its specific indication; adding an unregulated compound to an approved regimen isn't something the drug's own label anticipates or supports.

Which one should I actually ask my prescriber about?

If you're an adult without HIV-associated lipodystrophy asking about general GH support, sermorelin is the one with the longest regulatory paper trail (via Geref) and the mildest published side effect profile, which is why it tends to be the starting conversation for a provider-reviewed approach. It won't work if your pituitary can't respond, and a prescriber should confirm that with basic labs and history before starting anything. If you specifically have HIV-associated lipodystrophy with excess visceral abdominal fat, tesamorelin is the one with an actual FDA indication and phase 3 trial data behind it, and that's the conversation to have with an HIV specialist or endocrinologist. Hexarelin isn't a reasonable first, second, or third choice for most people reading this. It has no FDA approval for any human use, the weakest recent human safety data of the three, and known issues with cortisol, prolactin, and fast-fading effect. If a source is pushing hexarelin over the other two without mentioning any of that, that's a red flag about the source, not a reason to try hexarelin. For sermorelin specifically, a full walkthrough of what it does, how it's dosed, and where the evidence stands lives on the sermorelin hub page, and a provider-reviewed path through a legitimate, accredited pharmacy is the way to actually start, rather than ordering research-labeled peptides online.

Frequently asked questions

Is hexarelin stronger than sermorelin?

Hexarelin produces a bigger single GH spike in short-term measurements because it works through a different receptor pathway, but 'stronger' isn't the same as 'better' or 'safer.' It desensitizes quickly with repeat dosing and carries documented cortisol and prolactin side effects that sermorelin, as a GHRH analog, doesn't typically show at studied doses ^[2].

Is tesamorelin the same as sermorelin?

No. Both are GHRH analogs, but tesamorelin is a modified, more stable version specifically studied and FDA-approved for reducing visceral fat in HIV-related lipodystrophy ^[5]. Sermorelin has broader historical use (via the discontinued brand Geref) for GH reserve testing and pediatric GH deficiency, and is now available mainly through compounding pharmacies ^[3].

Why was Geref (sermorelin) discontinued?

Geref was discontinued for business reasons, not pulled for a safety failure or an FDA-mandated recall. The manufacturer stopped marketing the branded product in the US, which is why sermorelin today is obtained through compounding pharmacies under prescription rather than as an FDA-approved commercial drug ^[4].

Does insurance cover sermorelin, tesamorelin, or hexarelin?

Tesamorelin (Egrifta SV) can be covered by insurance when prescribed for its FDA-approved indication, HIV-associated lipodystrophy, though prior authorization is common ^[5]. Sermorelin, as a compounded product, is usually paid out of pocket. Hexarelin, sold only as a research chemical with no FDA approval, is never covered by insurance.

Can women use sermorelin, tesamorelin, or hexarelin?

Tesamorelin's trials and approval were conducted mainly in adults with HIV lipodystrophy regardless of sex, per its FDA labeling ^[5]. Sermorelin has been used diagnostically and therapeutically in both sexes historically. Hexarelin lacks controlled human trial data in either sex, so specific guidance for women doesn't really exist in the literature.

What is the difference between a GHRH analog and a growth hormone secretagogue?

A GHRH analog (sermorelin, tesamorelin) mimics the natural hypothalamic hormone that signals the pituitary through the GHRH receptor. A growth hormone secretagogue like hexarelin works through the separate ghrelin receptor pathway. Both raise GH, but through different receptors, with different downstream effects on hormones like cortisol and prolactin ^[1][2].

Is sermorelin as effective as HGH?

Not in every scenario. Sermorelin works only if the pituitary can still respond, so in confirmed severe GH deficiency or pituitary failure, direct HGH is more reliable and better studied. In people with a functioning pituitary wanting a more physiologic nudge to GH pulsing, sermorelin is gentler, but it isn't a direct substitute for HGH's predictable, immediate hormone delivery.

How is tesamorelin different from regular sermorelin in terms of FDA status?

Tesamorelin (Egrifta SV) currently holds active FDA approval for one specific indication, HIV-associated lipodystrophy ^[5]. Sermorelin was FDA approved historically under the brand Geref, but that approval no longer applies to a currently marketed product since the brand was discontinued; sermorelin today is compounded rather than commercially FDA-approved ^[3][4].

What are the long-term risks of hexarelin use?

Long-term human data on hexarelin is very limited since it's never gone through formal clinical trials or FDA review. The concerns raised in existing pharmacology literature include chronically elevated cortisol and prolactin, and rapid loss of GH-releasing effect with repeated dosing (tachyphylaxis), which undercuts any long-term benefit even before weighing hormonal side effects ^[2].

Can I stack hexarelin with sermorelin or tesamorelin for better results?

Mechanistically, combining a ghrelin-pathway compound with a GHRH analog can produce additive GH release in short studies ^[2]. But no large trial has tested this combination for safety or a real health outcome in humans, so anyone considering it is relying on mechanism and small studies, not outcomes evidence.

Which is cheaper: sermorelin, tesamorelin, or hexarelin?

Hexarelin is usually the cheapest per vial because it's sold unregulated as a research chemical with no FDA oversight or GMP verification. Sermorelin, compounded under prescription, costs more but includes pharmacy accountability. Tesamorelin (Egrifta SV), a branded FDA-approved specialty drug, is typically the most expensive without insurance coverage.

Does sermorelin or tesamorelin raise IGF-1 levels?

Yes, both are designed to raise GH output, which in turn raises IGF-1, and prescribers typically monitor IGF-1 as a marker of response and to avoid pushing levels too high. Tesamorelin's label specifically notes IGF-1 increases as an expected and monitored effect of treatment ^[5].

Sources

1. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pituitary Gland Disorders overview: GHRH analogs work by mimicking the natural hypothalamic hormone that stimulates pituitary GH release
2. Bowers CY, "Growth hormone-releasing peptide (GHRP)", Cellular and Molecular Life Sciences 1998, PMID 9560240: Hexarelin-type growth hormone secretagogues act via the ghrelin receptor pathway, show tachyphylaxis with repeated dosing, and raise cortisol and prolactin
3. U.S. Food and Drug Administration, Geref (sermorelin acetate) approval, NDA 019856: Sermorelin acetate was FDA approved under the brand Geref for diagnostic GH reserve testing and pediatric GH deficiency
4. U.S. Food and Drug Administration, Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book): Geref was discontinued as a marketed product; sermorelin is now primarily available via compounding pharmacies
5. U.S. Food and Drug Administration, Egrifta SV (tesamorelin for injection) prescribing information, NDA 209870: Tesamorelin is FDA-approved specifically to reduce excess abdominal fat in HIV-infected patients with lipodystrophy, dosed at 1 mg daily subcutaneously
6. Falutz J, et al. "Effects of tesamorelin on visceral fat and liver fat in HIV patients with abdominal fat accumulation", New England Journal of Medicine 2007, PMID 18184958: Tesamorelin trials showed reduced visceral adipose tissue over 26 weeks compared to placebo in HIV lipodystrophy patients
7. MedlinePlus (National Library of Medicine), Sermorelin injection drug information: Sermorelin is dosed by subcutaneous injection, typically at bedtime, to work with the body's natural nighttime GH pulse
8. National Cancer Institute, Growth Hormone and Cancer Risk fact sheet: Supraphysiologic growth hormone and IGF-1 levels have been studied for their association with cancer and cardiovascular risk